Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Table of contents

November 2007 - Volume 66 - suppl 3

Advances in targeted therapies IX

Annals of the Rheumatic Diseases: 66 (suppl 3)

Preface

Advances in targeted therapies IX (12 October, 2007)

Consensus statement

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 (12 October, 2007)
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, M E Weinblatt

Opening lectures

Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis (12 October, 2007)
Y Vasilopoulos, V Gkretsi, M Armaka, V Aidinis, G Kollias
New therapies for sepsis: focus on the interleukin (IL)12 family member IL27 (12 October, 2007)
Interpreting measurements of physical function in clinical trials (12 October, 2007)
Thoughts on health economics in rheumatoid arthritis (12 October, 2007)

Looking at clinical trials and more

Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? (12 October, 2007)
Tore K Kvien, Turid Heiberg, Kåre B Hagen
Joint remodelling in inflammatory disease (12 October, 2007)

Animal models

Amplifying elements of arthritis and joint destruction (12 October, 2007)
Wim B van den Berg, Peter L van Lent, Leo A B Joosten, Shahla Abdollahi-Roodsaz, Marije I Koenders

Novel targets I

Schnurri-3 is an essential regulator of osteoblast function and adult bone mass (12 October, 2007)
Dallas C Jones, Marc N Wein, Laurie H Glimcher
α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs (12 October, 2007)
Thomas A Luger, Thomas Brzoska

Insights from investigator-driven trials and genetics

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility (12 October, 2007) Free
M F Bakker, J W G Jacobs, S M M Verstappen, J W J Bijlsma

The lupus connection

Disease activity assessment in SLE: do we have the right instruments? (12 October, 2007)
Systemic lupus erythematosus: new molecular targets (12 October, 2007)
José C Crispín, Vasileios Kyttaris, Yuang-Taung Juang, George C Tsokos

Novel targets II

Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy (12 October, 2007)
Elena Gonzalez-Rey, Per Anderson, Mario Delgado
Update on toll-like receptor-directed therapies for human disease (12 October, 2007)
Kevin Tse, Anthony A Horner
Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue (12 October, 2007)
Sandra M Sacre, Stefan K Drexler, Evangelos Andreakos, Marc Feldmann, Fionula M Brennan, Brian M J Foxwell

Novel targets III

Interplay between pathogenic Th17 and regulatory T cells (12 October, 2007)
Regulatory T cells and toll-like receptors: regulating the regulators (12 October, 2007)
Roger Sutmuller, Anja Garritsen, Gosse J Adema

Issue Information